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1. Introduction  
Diabetic nephropathy (DN) is one of the consequences of a long-term diabetes, typically 
defined by macroalbuminuria—that is, a urinary albumin excretion of more than 300 mg in 
a 24-hour collection—or macroalbuminuria and abnormal renal function as represented by 
an abnormality in serum creatinine, calculated creatinine clearance, or glomerular filtration 
rate (GFR). ¹  
2. Prevalence 
Long-term microvascular and neurologic complications cause major morbidity and 
mortality in patients with insulin-dependent diabetes mellitus (IDDM) ². The incidence of  
overt nephropathy rapidly grows 10-15 years after the onset of type 1 diabetes mellitus; the 
incidence of nephropathy declines after that period and the occurence of nephropathy after 
35 years of duration of type 1 diabetes is uncommon.   Diabetic nephropathy rarely develops 
before 10 years' duration of IDDM. The peak incidence (3% per year) is usually found in 
persons who have had diabetes for 10-20 years. The increased mortality risk in long-term 
T1DM may be due to nephropathy, which may account for about 50% of deaths. 
Epidemiologic data derived from one of the studies – EDC – showed that in group of 
patients aged <18 and with the duration of diabetes over 5 years the prevalence of 
microalbuminia reached as much as 14%.  Long-term diabetes further increased the 
prevalence of albuminiria, thus 80% of male and 50% of female patients having diabetes up 
to 30 years of duration had proteinuria in micro- or macroalbuminuric range. (³-4)  
3. What is microalbuminuria 
Microalbuminuria is a marker for more serious proteinuria followed by azotemia in type 1 
diabetic nephropathy5 . Microalbuminuria develops in 40-60% type 1 diabetic patients and 
over 50% of patients with microalbuminuria evolve to macroalbuminuric stage e.g. 
advanced phase of overt diabetic nephropathy.  
4. Risk factor for diabetes nephropathy 
Reported risk factors for the development of diabetic renal disease include a longer duration 
of IDDM, an earlier age at the time of diagnosis, onset of puberty, poorer glycemic control 
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during the first five years of diabetes, smoking, and a family history of diabetic 
nephropathy.6-7  
Some of the factors leading to occurrence of diabetic nephropathy are hereditary 
predisposition (ACE genotype), poor glycemic control, diabetes - induced hyperfiltration, 
tissue hypoxia owing to reduction in capillary permeability, and increased postcapillary 
resistance . The capillary changes are caused by accumulation of glycated proteins and 
interaction of these proteins with cellular elements in the capillary walls, that effectuate the 
decrement in capillary ability for dilatation and ultimately, lead to capillary obstruction. In 
diabetes, morphological changes in type 4 collagen, heparin – sulphat proteoglycane, 
fibronectin and enectin molecules leads to structural and functional changes in basal 
membrane of the renal capillary bed . 8  
The theory of a reduction in nephron number at birth indicates that individuals born with a 
reduced number of glomeruli may be predisposed to subsequent renal injury and 
progressive nephropathy. This has been shown in animal studies in which the mother was 
exposed to hyperglycemia at the time of pregnancy. If this linkage is true in humans, that 
would have important implications concerning the role of maternal factors in the eventual 
development of kidney disease.  1    
Certain ethnic groups, particularly African Americans, persons of Hispanic origin, and 
American Indians, may be particularly disposed to renal disease as a complication of 
diabetes. 
5. Pathology and patohistologic changes in diabetic nephropathy 
The earliest morphologic abnormality in diabetic nephropathy is the thickening of the 
glomerular basement membrane (GBM) and expansion of the mesangium due to 
accumulation of extracellular matrix. Light microscopy findings in diffuse diabetic 
nephropathy show an increase in the solid spaces of the tuft, most frequently observed (by 
the positive periodic-acid Schiff reaction) as coarse branching of solid material. Large 
acellular accumulations also may be observed within these areas. These are circular on 
section and are known as the Kimmelstiel-Wilson lesions/nodules. Three major histologic 
changes occur in the glomeruli of persons with diabetic nephropathy. First, mesangial 
expansion which may be directly induced by hyperglycemia, perhaps via increased matrix 
production or glycation of matrix proteins. Second, a glomerulal basement membrane 
thickening may occur. Third, glomerular sclerosis being caused by intraglomerular 
hypertension (induced by renal vasodilatation or from ischemic injury induced by hyaline 
narrowing of the vessels supplying the glomeruli). These different histological patterns 
appear to have similar prognostic significance. 
Hyperglycemia induces diverse metabolic changes which may give birth to variety of 
microvascular lesions. The glycation (also called non-enzymatic glycosilation) of proteins is 
a process induced by the incubation of soluble proteins in the solution with a high glucose 
concentrations.  Glucation lead to three-dimensional structural and/or functional alterations 
of the proteins involved:  thus, the glycation of the erythrocyte membrane proteins leads to 
its increased adherence ability; likewise, the glycation of heparin – sulphate proteoglycans 
leads to proliferation of mesangial cells.  
High glucose level induces activation of polyol metabolic pathway resulting in increased 
sobritol production. Sorbitol, in turn, reduces intracellular myoinositol levels leading to 
increased capillary permeability and structural basal membrane changes. 9  
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Hyperglycemia increases the expression of transforming growth factor-beta (TGF-beta) in 
the glomeruli and of matrix proteins specifically stimulated by this cytokine. TGF-beta may 
contribute to the cellular hypertrophy and enhanced collagen synthesis observed in persons 
with diabetic nephropathy. 10 High glucosae levels may also may activate protein kinase C, 
which further contribute to renal disease and other vascular complications of diabetes. 
 
 
Fig. 1. Nodular glomerularsclerosis – Nodular glomerulosclerosis in the kidney of a patient with 
diabetic nephropathy. US Federal Government public domain image. Source: CDC. (This image was 
copied from wikipediaen)  
Tissue hypoxia, augmented capillary permeability and capillary blood flow are the factors 
which cause increased production of angiotensin II in 45% of diabetics. Angiotensin II might 
generate precapillary and capillary hypertension. The presence of risk factors for hypertension 
is particularlly important in patients with relatively poor glucose control (hemoglobin A1 
concentration above 12 percent). These patients are at increased risk of developing overt 
nephropathy within 20 years. 11. Furthermore, the risk for developing diabetic nephropathy in 
adolescents with type 1 diabetes whose parents suffered hypertension is threefold increased. 12  
The effects of prostaglandin PGI2 produced by hyperertrophic mesangial cells and  atrial 
natriuretic polypeptide  may be important in development of microvascular complications 
including diabetic nepropathy.  
In our previous study13, performed among the 55 pediatric patients with type 1 diabetes, 
who had urinary albumin excretion in the range of microalbuminuria was found in almost 
half (17 of 35 e.g. 48.6%) of children  with diabetic ketoacidosis. Furthermore, among the 20 
patients with normoalbuminuric UAE only 3 (15.0%) had ketoacidosis. 
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Fig. 2. Showing the correlations between the level of UAE and main parameters of acid-base 
staus. 
 
 
Fig. 3. The pathogenesis of diabetic nephropathy, Soman SS, Soman AS>Diabetic 
Nephropathy eMedicine Specialities, Endocrinology, Diabetes Mellitus, 2009. 
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The results of the study13 revealed a quite significant correlation between  microalbuminuria  
and plasma pH and bicarbonates; moreover, the level of plasma bicarbonate was a very 
good predictor of UAE values, depicting the aggravation of urinary albumin excretion in a 
response to the development of diabetic ketoacidosis   
6. Alterations in renal function in diabetic nephropathy 
There are 5 clinical stages of diabetic nephropathy. In the first stage, there is the substantial 
increase of glomerular filtration rate. Hyperglycemia and the lack of insulin along with 
several other hormones and factors undoubtedly contribute to development of 
hyperfiltration. The increase in glomerular filtration rate correlates with the enlargement of 
total filtration surface owing to glomerular hypertrophy; the latter reaches as much as 80% 
of the values existing prior to diabetes.   
In the second (“silent”) phase hypefunctional periods alternate the periods of normal function, 
and vice-versa. The periodicity of these alterations depend on quality of metabolic control. 
Glomerular filtration rate is, therefore, variable, arterial blood pressure is mainly within the 
normal range, although a mild hypertension might be present; UAE excretion rate is normal.  
The third stage (the incipient nephropathy) is characterized by UAE within 
microalbuminuric range (30-3oo mg/24 h ), there is progressive increment of arterial blood 
pressure, usually 5-15mmHg above the normal values, while the glomerular filtration rate 
may be normal, increased or reduced.  
In our previous study, the total of 40% microalbuminuric children had systolic prehypertension 
and systolic hypertension (17.1% and 22.9%, respectively) and even 60% had diastolic blood 
pressure disorders: diastolic prehypertension was found in 35%  and diastolic hypertension in 
25% patients with microalbuminuria. While the microalbuminuric patients had significantly 
higher blood pressure comparing to normoalbuminuric group, its noteworthy that the 
percentage (15% with systolic and 20% with diastolic disturbances) of prehypertensive and 
hypertensive patients among the type 1 diabetic children with normal UAE was also relatively 
high (Fig.1 and 2). The level of blood pressure correlated significantly with UAE, but was not 
proved to be a predictor of microalbuminuria in children with type 1 diabetes. 
The fourth stage, also known as manifest nephropathy, a clinically manifest proteinuria 
ensues, with UAE excretion rate exceeding 3oo mg/24h; albuminuria tends to be 
progressive, possibly leading to the clinical manifestations of nephritic syndrome. As 
nephropathy evolves to early overt stage with proteinuria (UAE >300 mg/24 hr, or >200 
μg/min), it is accompanied by hypertension. The arterial blood pressure is generally raised 
by 7% per year, followed by the variable reduction in glomerular filtration rate. In the 
majority of patients, in the midst of this phase a manifest renal insufficiency characterized 
by overt azotemia occurs. The fourth and fifth stages almost never occur in children and are 
quite rare in adolescents, mostly being related to the adult population.  
The fifth phase (renal insufficiency) is characterized by the general glomerular collapse, 
followed by overt azotemia, manifest proteinuria and grave hypertension.  
Microalbuminuria is also a well-established marker of increased CVD risk 15-16  
At the beginning, proteinuria is mild and intermittent and may remain that way during 5-10 
years following the first discovery. However, an increase of the amount of excreted protein 
and of frequency of proteinuric episodes might be expected afterwards. The beginning of 
retinopathy may precede or follow the occurrence of nephropathy, but in the later stages 
these two diabetic complications usually have roughly parallel course.       
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Fig. 4 and 5. Showing the percentage of blood pressure disturbances in microalbuminuric 
and normoalbuminuric group of children with type 1 diabetes . 
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Phase of constant and massive proteinuria may follow the stage of intermittent proteinuria. 
During the period, serum creatinine remains normal or slightly increased. The duration of 
this stage may be variable. Its course may accelerate leading to terminal renal insufficiency. 
The first sign of this acceleration is the rise in serum creatinine level.  
Advanced stage nephropathy is defined by a progressive decline in renal function (declining 
glomerular filtration rate and elevation of serum blood urea and creatinine), progressive 
proteinuria, and hypertension. Progression to end-stage renal disease (ESRD) is recognized 
by the appearance of uremia, the nephritic syndrome.  
 
 
Fig. 6. Soman SS, Soman AS: Diabetic Nephropathy eMedicine Specialities, Endocrinology, 
Diabetes Mellitus, 2009. 
7. The clinical features and laboratory findings in diabetic nephropathy 
The first system manifestation of diabetic nephropathy is the occurrence of peripheral 
oedema usually on ankles. Contrary to the widely accepted conviction that only 
hypoalbuminemia gives rise to ankle oedema, the direct cause of this symptom is usually 
not found. It seems that the pathogenesis of this symptom is quite complex. In most of the 
patients, the frail capillary walls are detected very often and, thus, the oedema might be due 
to increased capillary permeability.   
Regardless of cause, the peripheral oedema always indicate advanced stage of diabetic 
nephropathy and the occurrence and extent of the swelling is dependent on the duration of 
clinically manifest  proteinuria.  Also, the complaints related to lower leg muscle cramps are 
not unusual.  
Hypertension: Incipient to mild structural glomerular lesions do not correlate with the raise 
in arterial blood pressure. However, in the advanced stage of diabetic nephropathy the 
arterial hypertension is almost always present and relates with the duration of clinically 
manifest proteinuria.  
Some of our previous results13 showed a very good correlation between the level of urinary 
albumin excretion and the values of systolic and diastolic arterial blood pressure. Still, the 
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arterial blood pressure level was not predictive for microalbuminuria, judging by the 
multiple regression analysis, as already stated above. 
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Fig. 7. Showing the relation between the arterial blood pressure level and UAE values 
Paradoxally, however, there is no good correlation between the reduction in glomerular 
filtration rate and the rise in arterial blood pressure 17-18.Yet, most certainly, the therapy aimed 
at lowering high blood pressure leads to slowing down in reduction of glomerular filtration.    
Macroproteinuria: The amount of proteins daily excreted in patients with diabetic 
nephropathy ranges from the minimal concentrations of 30 mg/day to more than 20g/day. 
The average excretion is about 2,5g/24h. In about 20% of patients with nephropathy the 
amount is less than 1g/day and in 15% it exceeds 5g/day (nephritic syndrome).  Therefore, 
although proteinuria is considered a marker of of chronic diabetic nephropathy, yet it 
relatively rarely reach the nephritic range. 
Other symptoms of kidney disease include loss of sleep, poor appetite, upset stomach, 
weakness, and difficulty concentrating. Characteristic signs are: 
 Going to the bathroom more often at night  
 Less need for insulin or antidiabetic medications  
 Morning sickness, nausea, and vomiting  
 Weakness, paleness, and anemia  
 Itching  
8. Differential diagnosis 
Other pathological states of potential significance in differential diagnosis are: 
 Cholesterol embolization  
 Chronic obstruction  
 Interstitial nephritis  
 Amyloidosis  
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Disease Differentiating Signs/Symptoms Differentiating Tests 
Non diabetic 
kidney disease 
 Since both diabetes mellitus and 
chronic kidney disease (CKD) are 
common disorders, patients with 
both conditions may or may not have 
DN. A diagnosis other than DN 
should be considered if: there is a 
rapid progression of renal failure, 
evidence of another systemic disease, 
or short duration of diabetes 
(although onset is insidious in type 2, 
and DN may occasionally be the 
presenting manifestation of type 2 
DM). 
 Minimal proteinuria may indicate 
nondiabetic kidney disease. 
 Other specific diagnostic tests for 
other systemic disorders associated 
with nondiabetic kidney disease 
may be positive. 
Multiple 
myeloma (MM) 
 Multiple myeloma (MM) patients also 
may present with renal failure and 
proteinuria. 
 Symptoms of bone pain and anemia 
are the most common presenting 
features, affecting 80% of patients 
with MM. 
 The characteristic test results that 
differ from DN are: the presence of 
paraproteinemia/paraproteinuria; 
hypercalcemia; impaired 
production of normal 
immunoglobulin; and lytic bone 
lesions. Bataille R, Harousseau JL. 
Multiple myeloma. N Engl J Med. 
1997;336:1657-1664 
 Urinalysis with sulfosalicylic acid 
(SSA) was classically utilized to 
evaluate for discrepancy between 
albumin and total protein, as 
standard urinalysis dipstick 
detects albumin only. SSA causes 
precipitation of all of the urinary 
proteins, including paraproteins 
(Bence Jones proteins). 
 Serum protein electrophoresis 
(SPEP), urine protein 
electrophoresis (UPEP): 
paraprotein spike. 
 Serum and urine free light chains: 
increased concentrations of free 
light chain in serum. 
 Skull x-rays, CT or MRI bone: lytic 
lesions. 
 Bone marrow biopsy: plasma cell 
Proliferation 
Renal tract 
obstruction 
 Can be caused by stones, cancer, 
fibrosis, prostate 
hypertrophy/cancer, neurogenic 
bladder, or pelviureteric junction 
obstruction.  
 Obstruction to urine flow can result 
in postrenal failure. Symptoms 
 Passage of Foley catheter will 
result in flow of urine and relief of 
obstruction. 
 Kidney ultrasound: 
hydronephrosis, stones. 
 Prostate ultrasound: hypertrophy, 
cancer. 
www.intechopen.com
  
Type 1 Diabetes Complications 
 
254 
Disease Differentiating Signs/Symptoms Differentiating Tests 
include trouble passing urine, anuria, 
oliguria, hematuria, pain (with 
kidney stones), and urinary 
leakage/incontinence. Physical 
examination findings include 
enlarged prostate on rectal 
examination, costovertebral angle 
tenderness, suprapubic tenderness, 
and bladder fullness. 
 CT abdomen: hydronephrosis, 
stones, mass, congenital 
abnormalities, fibrosis. 
 PSA: elevated in BPH, prostate 
cancer. 
 MRI: not routine but may show 
hydronephrosis, stones, mass, 
congenital abnormalities, fibrosis 
Glomerulonep
hritis 
Glomerulonephritis, such as lupus 
nephritis and cryoglobulinemia, is in the 
differential for DN. Patient presentation 
and physical examination may be 
similar to that of DN. However, there 
may be symptoms and signs of other 
systemic disease, such as rashes or joint 
involvement. 
Urinalysis: hematuria, proteinuria, 
RBC casts, dysmorphic red cells. 
Albuminuria. 
Positive serology (e.g., ANA, ANCA, 
hepatitis serology). 
Complement: decreased in immune 
glomerulonephritis (e.g., lupus). 
Kidney biopsy: glomerulonephritis. 
Renal artery 
stenosis 
Renal artery stenosis presents either as 
hypertension refractory to multiple 
maximized antihypertensives or as 
renal failure shortly after the initiation 
of an ACE inhibitor. Physical 
examination is significant for an 
abdominal bruit. Safian RD, Textor SC. 
Renal-artery stenosis. N Engl J Med. 
2001;344:431-442 
Ultrasound, CT scan, MRI: shrunken 
kidney, decreased flow through the 
renal artery. 
Magnetic resonance angiography 
(MRA): renal artery stenosis. 
Renal angiogram: renal artery 
stenosis. 
Table 1. BMJ Group: Diabetic nephropathy, diferential diagnosis , epocrates online, 2010 
8.1 The diagnosis of diabetic nephropathy 19 
Patients with diabetes should be screened annually for DKD. Initial screening should 
commence: 
 5 years after the diagnosis of type 1 diabetes;  or  
 From diagnosis of type 2 diabetes.  
 Screening should include: 
 Measurements of urinary ACR in a spot urine sample;  
 Measurement of serum creatinine and estimation of GFR.  
An elevated ACR should be confirmed in the absence of urinary tract infection with 2 
additional first-void specimens collected during the next 3 to 6 months.  
 Microalbuminuria is defined as an ACR between 30-300 mg/g.  
 Macroalbuminuria is defined as an ACR > 300 mg/g.  
 2 of 3 samples should fall within the microalbuminuric or macroalbuminuric range to 
confirm classification.  
Using the CKD staging likelihood of DN can be determined as follows:  
- Normoalbuminuria in CKD stages 3 to 5 (GFR <60) is unlikely to be DN.  
- Microalbuminuria in CKD stages 1 to 3 (GFR >30) is possible DN. 
- Microalbuminuria in CKD stages 4 to 5 (GFR <30) is unlikely to be DN.  
- Macroalbuminuria at all stages of CKD is highly likely to be DN. 
www.intechopen.com
 Diabetic Nephrophaty in Children 
 
255 
Urinanalysis proteinuria 
Urinary albumin for creatinine ratio microalbuminuria: between 30 and 300 mg/g; 
macroalbuminuria: >300 mg/g 
Blood biochemistry elevated creatinine 
Serum creatinine with GFR estimation Glomerular filtration rate (GFR) may be raised 
in CKD stage 1, normal in CKD stage 2, and 
reduced in CKD stages 3 to 5 
Kidney ultrasound normal-to-large kidneys with increased 
echogenicity; may show hydronephrosis if 
vesiculopathy and/or obstruction is 
superimposed 
Table 2. Clinical tests in diagnosis of diabetic nephropathyClinical tests in diagnostics of 
diabetic nephropathy: 
 
Test Results 
24 hour urine to collection microalbuminuria: albumin 30 to 300 mg/24 
hours; macroalbuminuria: albumin >300 
mg/24 hours 
CT-abdomen hydronephrosis; wedge-shaped areas of low 
attenuation; loss of the ability to distinguish 
the corticomedullary border; perinephric 
stranding; cysts; masses; stones 
Magnet resonance angiography renal artery stenosis 
Doppler ultrasound may show renal artery stenosis 
Kidney biopsy mesangial expansion, fibrosis, Kimmelstiel-
Wilson nodules 
The source:  epocrates online com, 2010 
Table 3. Other tests to consider 
High blood pressure often goes along with diabetic nephropathy. You may have high blood 
pressure that develops rapidly or is difficult to control. 
9. Treatment and therapy 
Annual screening for microalbuminuria, with a random spot urine sample for 
microalbumin-to-creatinine ratio, should be initiated once the child is 10 years of age and 
has had diabetes for 5 years. 
Confirmed, persistently elevated microalbumin levels on two additional urine specimens 
should be treated with an ACE inhibitor titrated to normalization of microalbumin excretion 
if possible 
Once albuminuria is diagnosed, a number of factors attenuate the effect of hyperfiltration on 
kidneys: 
1. Control of hyperglycemia- The Diabetes Control and Complications Trial (DCCT) 21 and 
the United Kingdom Prospective Diabetes Study (UKPDS) 21 have definitively shown 
that intensive diabetes therapy can significantly reduce the risk of the development of 
microalbuminuria and overt nephropathy in people with diabetes. 
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Fig. 8. Showing the relation of the parameters of metabolic regulation and the UAE level in 
children with type 1 diabetes 
Accordingly the earlier study13 revealed that hemoglobin A1/c and, particularly, blood 
glucose level were significantly related to urinary albumin excretion rate. Furthermore, 
blood glucose was the major predictor of microalbuminuria in children with type 1 diabetes. 
Lowering A1C to an average of ~7% has been shown to reduce microvascular and 
neuropathic complications of diabetes and, possibly, macrovascular disease. Preliminary 
results of the multicenter A1C-Derived Average Glucose (ADAG) Trial, presented at the 
European Association for the Study of Diabetes meeting in September 2007, confirmed a 
close correlation of A1C with mean glucose in patients with type 1, type 2, or no diabetes. 
Final results of this study, not available at the time this statement was completed, should 
allow more accurate reporting of the estimated average glucose (eAG) and improve 
patients’ understanding of this measure of glycemia22  
Target HbA1c for people with diabetes should be < 7.0%, irrespective of the presence or 
absence of CKD. 23  
Considering the high incidence of overnight hypoglycemias, in children and adolescents 
during the optimal regulation of blood glucosae levels, the A1C level achieved in the 
“intensive” adolescent cohort of the DCCT group was >1% higher than that achieved by adult 
DCCT subjects and above current ADA recommendations for patients in general. Standards of 
Medical Care in Diabetes—2008 American Diabetes Association Tight glycemic control will 
delay the progression of microalbuminuria and slow the progression of diabetic nephropathy. 
2. Aggressive control of systemic blood pressure- In patients with type 1 diabetes, 
hypertension is usually caused by underlying diabetic nephropathy and typically becomes 
manifest about the time that patients develop microalbuminuria . Hypertension in 
childhood is defined as an average systolic or diastolic blood pressure ≥95th percentile for 
age, sex, and height percentile measured on at least three separate days. “High-normal” 
blood pressure is defined as an average systolic or diastolic blood pressure ≥90th but <95th 
percentile for age, sex, and height percentile measured on at least three separate days. 
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Treatment of hi gh-normal blood pressure (systolic or diastolic blood pressure consistently 
above the 90th percentile for age, sex, and height) should include dietary intervention and 
exercise aimed at weight control and increased physical activity, if appropriate. If target 
blood pressure is not reached with 3–6 months of lifestyle intervention, pharmacologic 
treatment should be initiated.  
Pharmacologic treatment of hypertension (systolic or diastolic blood pressure consistently 
above the 95th percentile for age, sex, and height or consistently >130/80 mmHg, if 95% 
exceeds that value) should be initiated as soon as the diagnosis is confirmed. 
The principal agents for lowering high blood pressure are angiotensin convertase inhibitors  
(ACE). The beneficial effect of ACE inhibition on preventing progression from 
microalbuminuria to overt diabetic nephropathy is long-lasting (8 y) and is associated with 
the preservation of a normal GFR. ACE-I reduces the risk of progression of overt type 1 
diabetic nephropathy to ESRD and in type 1 patients with microalbuminuria to overt 
nephropathy. 25  The results of multicentric studies showed that blood pressure in patients 
with chronic renal insufficiency should be lowered below normal range (as recommended 
by WHO) in order to achieve beneficial effect on progression of the disease.  
A meta-analysis of several small studies has shown that protein restriction may be of benefit 
in some patients whose nephropathy seems to be progressing despite optimal glucose and 
blood pressure control 26 
Hypertensive people with diabetes and CKD stages 1-4 should be treated with an ACE 
inhibitor or an ARB (Angiotensin Receptor Blocer), usually in combination with a 
diuretic27    
If needed to achieve blood pressure targets, a thiazide diuretic should be added to those 
with an estimated glomerular filtration rate (GFR) (see below) ≥50 ml/min per 1.73 m2 and 
a loop diuretic for those with an estimated GFR <50 ml/min per 1.73 m2. (E) 
Normotensive people with diabetes and macroalbuminuria should be treated with an ACE 
inhibitor or an ARB.In type 1 diabetes with macroalbuminuria, ACE inhibitors decrease 
albuminuria and reduce the risk of clinical outcomes regardless of the presence or absence 
of hypertension. A randomized controlled trial in people with type 1 diabetes and 
macroalbuminuria found that ACE inhibitors reduced the risk of the combined outcome of 
doubling of serum creatinine level, CKD stage 5, and death. 28 A quarter of the participants 
were normotensive. There was no significant difference in the treatment effect between the 
normotensive and hypertensive individuals.  
Future agents: Wenzel et al. 29 . have examined the role of avosentan (endothelin antagonist) 
on progression of microalbuminuria. Avosentan  have demonstrated antifibrotic, anti-
inflammatory, and antiproteinuric effects in experimental studies. Wenzel et al conducted a 
randomized, placebo-controlled, double-blind, parallel-design, dosage-range study on the 
effect of the endothelin-A antagonist avosentan (SPP301) on urinary albumin excretion rate 
in 286 patients with diabetic nephropathy, macroalbuminuria, and a blood pressure of 
<180/110 mm Hg.  All dosages of avosentan, administered in addition to standard ACE 
inhibitor/ARB treatment, were found to reduce the mean relative urinary albumin excretion 
rate (-16.3% to -29.9%, relative to baseline) in the study's patients. 
3. Selective control of arteriolar dilation by use of angiotensin-converting enzyme (ACE) 
inhibitors (thus decreasing transglomerular capillary pressure) This is particularly 
significant when lowering of systemic blood pressure is accompanied with concomitant 
lessening of glomerular capillary pressure. however the optimal lower limit for systolic 
blood pressure is unclear. 30  
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4. Dietary protein restriction (because high protein intake increases renal perfusion rate).  
A meta-analysis examining the effects of dietary protein restriction (0.5-0.85 g/kg/d) in 
diabetic patients suggested a beneficial effect on the GFR, creatinine clearance, and 
albuminuria. However, a large, long-term prospective study is needed to establish the 
safety, efficacy, and compliance with protein restriction in diabetic patients with 
nephropathy. Considering the importance and role of dietary proteins in the process of 
growth and development,  a sharp restriction (<15% of total daily amount of nutrients) of 
proteins in adolescents with diabetic nephropathy is not justified.  
Other standard modalities for the treatment of progressive renal disease and its 
complications (e.g., osteodystrophy) must also be used when indicated, such as sodium and 
phosphate restriction and use of phosphate binders. When the GFR begins to decline 
substantially, referral to a physician experienced in the care of such patients is indicated. 
Radiocontrast media are particularly nephrotoxic in patients with diabetic nephropathy, and 
azotemic patients should be carefully hydrated before receiving any procedures requiring 
contrast that cannot be avoided. 31 
As for any other patient with ESRD, diabetic patients with ESRD can be offered 
hemodialysis, peritoneal dialysis, kidney transplantation, or combined kidney-pancreas 
transplantation. 
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